Sec Form 3 Filing - Madsen Julia @ STERIS plc - 2020-07-28

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Madsen Julia 2. Issuer Name and Ticker or Trading Symbol STERIS plc [ STE] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Senior VP, Life Sciences (Last) (First) (Middle) C/O 70 SIR ROGER'S QUAY 3. Date of Earliest Transaction (MM/DD/YY) 07/28/2020 (Street) DUBLIN, L22 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares 3,245 ( 1 ) D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (right to buy) $ 45.34 ( 2 ) 05/31/2023 Ordinary Shares 1,100 D Employee Stock Option (right to buy) $ 53.52 ( 2 ) 05/30/2024 Ordinary Shares 800 D Employee Stock Option (right to buy) $ 66.15 ( 2 ) 05/28/2025 Ordinary Shares 700 D Employee Stock Option (right to buy) $ 69.72 ( 2 ) 06/01/2026 Ordinary Shares 2,700 D Employee Stock Option (right to buy) $ 77.07 ( 3 ) 05/30/2027 Ordinary Shares 3,252 D Employee Stock Option (right to buy) $ 114.22 ( 4 ) 05/31/2028 Ordinary Shares 2,872 D Employee Stock Option (right to buy) $ 147.05 ( 5 ) 05/31/2029 Ordinary Shares 2,136 D Employee Stock Option (right to buy) $ 182.22 ( 6 ) 06/01/2030 Ordinary Shares 2,984 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Madsen Julia C/O 70 SIR ROGER'S QUAY DUBLIN, L22 Senior VP, Life Sciences Signatures /s/ Ronald E. Snyder, Authorized Representative under Power of Attorney 08/03/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )1,318 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 308 on June 1, 2021; 121 on June 1, 2021; 92 on June 1, 2021; 123 on June 1, 2021; 121 on May 31, 2022; 92 on May 31, 2022; 123 on June 1, 2022; 92 on May 31, 2023; 123 on June 1, 2023; 123 on June 3, 2024. ( 2 )This option is fully vested. ( 3 )This option becomes exercisable as follows: 813 May 30, 2018; 813 on May 30, 2019; 813 on May 30, 2020; and 813 on June 1, 2021. ( 4 )This option becomes exercisable as follows: 718 on May 31, 2019; 718 on May 31, 2020; 718 on June 1, 2021; and 718 on May 31, 2022. ( 5 )This option becomes exercisable as follows: 534 on May 31, 2020; 534 on June 1, 2021; 534 on May 31, 2022; and 534 on May 31, 2023. ( 6 )This option becomes exercisable as follows: 746 on June 1, 2021; 746 on June 1, 2022; 746 on June 1, 2023; and 746 on June 3, 2024.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.